|
|
|
CIPROFOL |
PROPOFOL |
CIPROFOL |
PROPOFOL |
CIPROFOL |
PROPOFOL |
CIPROFOL |
PROPOFOL |
CIPROFOL |
PROPOFOL |
Zeng Y 2022 |
multicenter, randomized, open-label, propofol-controlled
phase 2 clinical trial |
40 |
|
11 (36.7) |
3 (30.0) |
42.5 ± 10.3 |
46.4 ± 11.2 |
23.7 ± 3.0 |
23.6 ± 3.6 |
16/14/0/0 |
4/6/0/0 |
105.3 ±
62.6 |
Wang X 2022 |
phase 3, multicenter, randomized, double-blind,
comparative study |
176 |
|
32 |
31 |
38.5 (12.1) |
41.1 (11.1) |
23.3
(2.9) |
23.3 (3.1) |
51/37/0/0 |
48/40/0/0 |
- |
Qin K 2022 |
prospective, randomized, single-blind study |
105 |
|
18
(34.6) |
18 (34.0) |
39.00±10.10 |
41.25±10.63 |
23.38±3.33 |
22.63±2.38 |
0/0/42/10 |
0/0/44/9 |
175.88±42.22 |
Chen-Ben Zhen 2022 |
prospective, double-blind, single-center study |
120 |
|
- |
- |
33.9±9.1 |
33.8±9.6 |
22.2±3.2 |
21.4±2.8 |
32/28/0/0 |
34/26/0/0 |
55.2±20.5 |
Liang Peng 2023 |
multicenter, single-blinded, propofol-controlled,
randomized, phase 3 trial |
128 |
|
23 (26.7) |
10 (23.8) |
38.5 ± 10.1 |
40.5 ± 10.1 |
23.3 ± 2.8 |
23.3 ± 3.0 |
48/38/0/0 |
22/20/0/0 |
94.6 ±
39.2 |
Zhu Qianmei 2023
|
phase 2a, 7-center, open-labeled, non-randomized and positive controlled
clinical trial
|
68
|
0.4mg
0.5mg
|
4
13
|
16
|
53.5 ± 8.3
46.6 ± 12.4
|
44.8 ± 12.4
|
24.4 ± 2.5
23.8 ± 2.6
|
24.4 ± 3.0
|
6/2/0/0
7/22/0/0
|
14/17/0/0
|
102.6 ± 44.4
81.8 ± 47.9
|
Man Yan 2023 |
randomized double-blind controlled study |
128 |
|
- |
- |
42.2±9.46 |
44.1±9.4 |
22.8±2.2 |
23.3±2.6 |
18/46/0/0 |
14/50/0/0 |
- |